Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Sequencing systemic therapies in advanced RCC: is there a best strategy?

Powles T, Crusz SM.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e172. Review.

2.

Sorafenib for the treatment of renal cancer.

Strumberg D.

Expert Opin Pharmacother. 2012 Feb;13(3):407-19. doi: 10.1517/14656566.2012.654776. Epub 2012 Jan 20. Review.

PMID:
22263843
3.

Second-line therapy for refractory renal-cell carcinoma.

Zustovich F, Lombardi G, Nicoletto O, Pastorelli D.

Crit Rev Oncol Hematol. 2012 Jul;83(1):112-22. doi: 10.1016/j.critrevonc.2011.08.008. Epub 2011 Sep 22. Review.

PMID:
21944739
4.

Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.

Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T.

Jpn J Clin Oncol. 2014 May;44(5):479-85. doi: 10.1093/jjco/hyu018. Epub 2014 Mar 30.

PMID:
24688083
5.

Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

Busch J, Seidel C, Erber B, Issever AS, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2013 Jul;64(1):62-70. doi: 10.1016/j.eururo.2012.09.004. Epub 2012 Sep 11.

PMID:
22999519
6.

Optimizing recent advances in metastatic renal cell carcinoma.

Courtney KD, Choueiri TK.

Curr Oncol Rep. 2009 May;11(3):218-26. Review.

PMID:
19336014
7.

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.

Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S.

Br J Cancer. 2011 Nov 22;105(11):1635-9. doi: 10.1038/bjc.2011.389. Epub 2011 Oct 27.

8.

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C, Bex A.

Eur Urol. 2015 Jan;67(1):100-10. doi: 10.1016/j.eururo.2014.04.006. Epub 2014 May 1. Review.

PMID:
24841777
9.

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.

Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R.

J Clin Oncol. 2010 May 1;28(13):2131-6. doi: 10.1200/JCO.2009.26.3152. Epub 2010 Apr 5.

PMID:
20368560
10.

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG.

Eur Urol. 2012 Feb;61(2):307-16. doi: 10.1016/j.eururo.2011.10.032. Epub 2011 Oct 30. Review.

PMID:
22055147
11.

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ.

Clin Genitourin Cancer. 2013 Mar;11(1):45-50. doi: 10.1016/j.clgc.2012.06.001. Epub 2012 Oct 4.

PMID:
23041453
12.

Second-line systemic therapy for the treatment of metastatic renal cell cancer.

Kruck S, Bedke J, Kuczyk MA, Merseburger AS.

Expert Rev Anticancer Ther. 2012 Jun;12(6):777-85. doi: 10.1586/era.12.43. Review.

PMID:
22716494
13.

Optimal management of metastatic renal cell carcinoma: current status.

Escudier B, Albiges L, Sonpavde G.

Drugs. 2013 Apr;73(5):427-38. doi: 10.1007/s40265-013-0043-1. Review.

PMID:
23572408
14.

The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.

Oudard S, Vano Y.

Curr Opin Urol. 2015 Sep;25(5):402-10. doi: 10.1097/MOU.0000000000000206. Review.

PMID:
26148068
15.

Future perspectives for mTOR inhibitors in renal cell cancer treatment.

Czarnecka AM, Kornakiewicz A, Lian F, Szczylik C.

Future Oncol. 2015;11(5):801-17. doi: 10.2217/fon.14.303. Review.

PMID:
25757683
16.

Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.

van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):77-88. doi: 10.1016/j.drup.2014.10.003. Epub 2014 Oct 7. Review.

PMID:
25457974
17.

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.

Albiges L, Escudier B.

Curr Opin Urol. 2015 Sep;25(5):367-73. doi: 10.1097/MOU.0000000000000197. Review.

PMID:
26153638
18.

Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.

Iacovelli R, Verzoni E, Grassi P, Farcomeni A, de Braud F, Procopio G.

Tumori. 2014 Nov-Dec;100(6):e282-5. doi: 10.1700/1778.19296.

PMID:
25688511
19.

Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.

Glen H.

Future Oncol. 2016 Oct;12(19):2195-204. doi: 10.2217/fon-2016-0215. Epub 2016 Jun 24. Review.

PMID:
27339111
20.

How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.

Escudier B.

J Clin Oncol. 2010 May 1;28(13):2125-6. doi: 10.1200/JCO.2009.27.4951. Epub 2010 Apr 5. No abstract available.

PMID:
20368540

Supplemental Content

Support Center